University of Michigan at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
University of Michigan brings 30 presentations to ASH 2026 in New Orleans. Its program spans leukemia biology, sickle cell disease and transplant outcomes. It covers mutations in the ZMIZ1 gene in early T-cell precursor leukemia and how social drivers of health relate to inflammation before transplant.
| Organization | ASH 2026 Attendance |
|---|---|
University of Michigan Ann Arbor, MI | |
Public research university in Ann Arbor with the Michigan Medicine academic medical center. | Symposium Fri Dec 11 11:00am–2:00pm Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum Bispecific antibodies in relapsed diffuse large B-cell and follicular lymphoma, from sequencing with CAR-T to outpatient step-up dosing and side effects. Session Fri Dec 11 1:35pm–3:55pm Symposium Fri Dec 11 3:00pm–6:00pm Hemophilia at the Crossroads: New Evidence for Individualized Care Tailoring hemophilia prevention with factor replacement, factor-mimicking drugs, rebalancing agents, and gene therapy to protect joints and ease treatment burden. Session Fri Dec 11 3:05pm–3:55pm Risk Factors of Clonal Hematopoiesis Factors that lead blood stem cells to acquire p53 mutations and expand, from the first mutation toward myeloid cancer. Session Fri Dec 11 3:45pm–4:25pm Epigenetic and Transcriptional Regulation of T-ALL Gene-control programs that set T-cell leukemia cell states and create dependencies that drugs could exploit. Talk Fri Dec 11 3:45pm–4:25pm Talk Fri Dec 11 4:38pm–5:18pm Oral Sat Dec 12 9:30am–11:00am Oral Sat Dec 12 9:30am–11:00am Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Poster Sat Dec 12 5:30pm–7:30pm Talk Sat Dec 12 6:00pm–8:00pm Talk Sat Dec 12 6:00pm–8:00pm Oral Sun Dec 13 9:30am–11:00am Oral Sun Dec 13 12:00pm–1:30pm Session Sun Dec 13 1:30pm–1:55pm Talk Sun Dec 13 4:30pm–5:45pm Management Considerations in Inherited Hemolytic Anemias How genetic testing is replacing stepwise diagnosis of inherited hemolytic anemias, with pyruvate kinase deficiency and mitapivat as a model of targeted therapy. Oral Sun Dec 13 4:30pm–6:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Poster Sun Dec 13 6:00pm–8:00pm Oral Mon Dec 14 10:30am–12:00pm Talk Mon Dec 14 4:30pm–6:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm Poster Mon Dec 14 6:00pm–8:00pm |
Find decision makers at University of Michigan
Tell us what you sell and we’ll find the people at University of Michigan most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction